8-K: Tactile Medical Q2 Revenue Up 7.8%, Updates 2025 Outlook

Tactile Systems Technology, Inc. reported a 7.8% year-over-year revenue increase to $78.9 million in Q2 2025, while net income and Adjusted EBITDA declined, leading to an updated full-year financial outlook.

Summary

• Total revenue for the second quarter of 2025 increased 7.8% year-over-year to $78.9 million, compared to $73.2 million in Q2 2024.
• Gross margin was 75% in Q2 2025, an increase from 74% in Q2 2024.
• Net income for Q2 2025 was $3.2 million, down from $4.3 million in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $7.7 million, compared to $9.1 million in Q2 2024.
• Airway clearance product line revenue increased 52% ($4.4 million) and lymphedema product line revenue increased 2% ($1.3 million) in Q2 2025.
• Operating expenses increased 13% to $54.7 million in Q2 2025, primarily due to planned strategic investments.
• For the first six months of 2025, total revenue increased 4% to $140.2 million, net income was $0.2 million, and Adjusted EBITDA was $7.4 million.
• Completed the $30.0 million share repurchase program, repurchasing $16.5 million of stock in Q2 2025 and $26.6 million year-to-date.
• As of June 30, 2025, cash and cash equivalents were $81.5 million, and outstanding borrowings were $24.8 million.
• On July 31, 2025, the company paid off its $24.0 million term loan and refinanced its revolving credit facility, increasing capacity from $25.0 million to $40.0 million.
• Full-year 2025 total revenue outlook was updated to a range of $310 million to $315 million (6% to 8% growth), up from the prior guidance of $309 million to $315 million.
• Full-year 2025 Adjusted EBITDA outlook was updated to a range of $33 million to $35 million, up from the prior guidance of $32 million to $34 million.

Sentiment

Score: 7

Explanation: While net income and Adjusted EBITDA saw year-over-year declines in Q2, the company exceeded revenue expectations and provided an upward revision to its full-year 2025 guidance for both revenue and Adjusted EBITDA. Strategic investments are ongoing, expected to yield more significant benefits in 2026, and the company successfully completed a share repurchase program and refinanced its debt, indicating financial flexibility.

Positives

• Total revenue increased 7.8% year-over-year to $78.9 million, exceeding previously stated expectations.
• Gross margin improved to 75% from 74% in Q2 2024, driven by lower manufacturing and warranty costs.
• Airway clearance product line revenue saw significant growth, increasing 52% ($4.4 million) year-over-year.
• Lymphedema product line revenue increased 2% ($1.3 million), attributed to increased sales force headcount and improved productivity.
• Completed the $30.0 million share repurchase program, demonstrating commitment to shareholder returns.
• Successfully retired a $24.0 million term loan and increased revolving credit facility capacity from $25.0 million to $40.0 million, enhancing financial flexibility.
• Updated full-year 2025 revenue guidance slightly upward at the low end ($310 million vs. $309 million previously).
• Updated full-year 2025 Adjusted EBITDA guidance upward ($33 million to $35 million vs. $32 million to $34 million previously).
• New clinical data was presented demonstrating significant benefits of Flexitouch Plus in treating head and neck cancer-related lymphedema.
• Strategic priorities for 2025, including sales force expansion, Nimbl adoption, and workflow simplification pilot programs, are progressing as planned and are expected to drive future growth.

Negatives

• Net income decreased to $3.2 million in Q2 2025 from $4.3 million in Q2 2024, representing a 25% decline.
• Adjusted EBITDA decreased to $7.7 million in Q2 2025 from $9.1 million in Q2 2024, a 15% reduction.
• Operating income declined to $4.1 million in Q2 2025 from $5.8 million in Q2 2024.
• Operating expenses increased 13% to $54.7 million, primarily due to planned strategic investments, impacting short-term profitability.
• Net income for the first six months of 2025 was $0.2 million, a substantial decrease from $2.1 million in the same period of 2024.
• Adjusted EBITDA for the first six months of 2025 was $7.4 million, down from $10.1 million in the comparable period of 2024.
• Cash and cash equivalents decreased to $81.5 million as of June 30, 2025, from $94.4 million as of December 31, 2024, partly due to share repurchases.

Risks

• Ability to obtain reimbursement from third-party payers for products.
• Adverse economic conditions, including inflation, rising interest rates, or a recession.
• Adequacy of liquidity to pursue business objectives.
• Price increases for supplies and components.
• Wage and component price inflation.
• Loss of a key supplier or other supply chain disruptions.
• Entry of new competitors and/or competitive products.
• Compliance with and changes in federal, state, and local government laws and regulations.
• Technological obsolescence of, or quality issues with, products.
• Ability to expand business through strategic acquisitions.
• Ability to integrate acquisitions and related businesses.
• Effects of current and future U.S. and foreign trade policy and tariff actions.
• Inability to carry out research, development, and commercialization plans.

Future Outlook

The company updated its full-year 2025 financial outlook, now expecting total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year. Full-year 2025 Adjusted EBITDA is now expected in the range of $33 million to $35 million. Management anticipates continued momentum through the second half of the year, supported by a favorable payer policy environment and healthy channel call points. Strategic priorities for 2025, including sales force expansion, Nimbl adoption, and workflow simplification pilot programs, are expected to unlock market opportunity and enable scalable, profitable growth, with more meaningful benefits anticipated in 2026.

Management Comments

• "We delivered strong financial performance in the second quarter, marked by total revenue growth of nearly 8% year-over-year and ahead of our previously stated expectations."
• "Supported by a favorable near-term payer policy environment and healthy channel call points, we are confident this momentum will continue through the second half of the year as we deploy our go-to-market strategies and commercial action plan."
• "We also remain highly focused on our three strategic priorities for 2025 to improve access to care, expand treatment options for lymphedema patients, and enhance the lifetime patient value."
• "Our key technology and people-related investments are continuing to progress, including strategically expanding our sales force, presenting new clinical data from our head and neck lymphedema trial, growing adoption of Nimbl, and launching pilot programs aimed at simplifying the workflow process of patient identification, referral, and order processing."
• "These priorities are designed to unlock our market opportunity and enable scalable, profitable growth, and we expect to begin benefiting more meaningfully from them in 2026."

Industry Context

Tactile Medical operates in the medical technology sector, specializing in at-home therapies for chronic conditions such as lymphedema and chronic pulmonary disease. The company's reported growth in both airway clearance products (AffloVest) and lymphedema products (Flexitouch Plus, Nimbl) indicates a strong position and expansion within these niche markets. The strategic focus on improving access to care and expanding treatment options aligns with broader healthcare trends towards decentralized, patient-centric care models and cost-effective home-based solutions. A favorable near-term payer policy environment suggests supportive regulatory and reimbursement conditions, which are crucial for growth in the medical device and therapy industry.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to provide a direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Positive impact from the completion of the share repurchase program and increased financial flexibility due to credit facility refinancing. Potential for future growth from strategic investments and updated positive guidance, though short-term profitability decline may be a concern.
• Patients: Positive impact from new data demonstrating benefits of Flexitouch Plus and ongoing efforts to improve access to care and expand treatment options for lymphedema patients.
• Employees: Strategic expansion of the sales force indicates potential for new hires and growth opportunities.
• Durable Medical Equipment (DME) Partners: Increased placements of AffloVest among DME partners suggest strong collaboration and business growth.

Next Steps

• Continue momentum through the second half of 2025 by deploying go-to-market strategies and commercial action plan.
• Continue progressing key technology and people-related investments, including strategically expanding the sales force.
• Continue growing adoption of Nimbl.
• Continue launching pilot programs aimed at simplifying the workflow process of patient identification, referral, and order processing.
• Expect to begin benefiting more meaningfully from strategic priorities in 2026.

Key Dates

Recommendation

While the company demonstrated strong revenue growth and improved gross margin, and updated its full-year guidance positively, the year-over-year decline in net income and Adjusted EBITDA in Q2 and YTD indicates short-term profitability pressures due to strategic investments. The completion of the share repurchase program and debt refinancing are positive for financial structure. The long-term outlook is promising with strategic initiatives expected to yield benefits in 2026. Given the mixed short-term results but positive forward guidance and strategic positioning, a "Hold" recommendation is appropriate for investors to observe the execution of strategic priorities and their impact on future profitability.

Keywords

Medical Technology, Lymphedema, Airway Clearance, Chronic Disorders, Home Therapies, Medical Devices, Healthcare, Financial Results, Earnings, Q2 2025, TCMD, Nasdaq, Flexitouch Plus, AffloVest, Nimbl